Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single ascending dose study of TIN816 in healthy Japanese adults
jRCT2051230105Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing TIN816 single ascending dose with Placebo (2 arms). Primary endpoints: Safety endpoints and Tolerability endpoints. Started Oct 2023; status: completed.
02
Drugs
TIN-816
Beyond the preview
Go deeper on jRCT2051230105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230105.